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Background: This study investigated the effects of indexes of consciousness (IoC1 and IoC2) monitoring on
remifentanil dosage.
Methods: In this randomized, single-blinded, prospective study, 120 patients undergoing unilateral modified radical
mastectomy were randomly assigned to the treatment group (T group, n = 60) or control group (C group, n = 60).
In the T group, patients received both IoC1 (sedation) and IoC2 (analgesia) monitoring, and remifentanil dosages
were adjusted by anesthetists according to IoC2. In the C group, remifentanil dosages were adjusted based on the
anesthetists’ judgment according to the patients’ vital signs. Remifentanil dose, adjustment frequency, infusion
duration, intraoperative adverse events, and quality of anesthetic recovery were compared between the two
groups. The primary outcome was the dose of remifentanil.
Results: Compared with the C group, mean remifentanil dosage was significantly higher in the T group (3.8 ± 1.9
versus 3.2 ± 1.2 μg kg-1 h-1, P < 0.05) during the anesthetic period, as was the adjustment frequency of target-
controlled infusion (2.9 ± 1.9 versus 2.0 ± 1.2 times/surgery, P < 0.05), but there was no difference in infusion
duration. Voluntary eye opening, extubation time, and recovery score were not significantly different between the
two groups (P > 0.05). Total adverse events were significantly reduced in the T group (P < 0.05).
Conclusions: IoC1-targeted propofol dosing does not seem to be significantly different to hemodynamic-based
monitoring, whereas IoC2 monitoring can increase remifentanil dosage during modified radical mastectomy, but
the anesthetic process is more controllable and total adverse events are reduced, which improves the controllability
of anesthesia.
Trial registration: Trial registration number: ChiCTR-TRC-13004101, registered on 27 November 2013.
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Depth of anesthesia is commonly assessed in clinical
practice by the patient’s clinical signs and symptoms
such as blood pressure, heart rate variability, and body
movement, but these measures are difficult to convert
into a quantitative standard measure. In addition, some
technologies are available for objective monitoring of* Correspondence: yujingui1109@126.com
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disadvantages [1] and body movements can be used as a
surrogate for pain [2]. In recent years, the index of con-
sciousness (IoC) has emerged as a new technique for
monitoring depth of anesthesia, which not only object-
ively measures the patient’s awareness level [3] but also
reflects analgesic status [2].
At present, many studies have focused on IoC1 moni-
toring for sedative depth [4, 5], but only a few studies
have focused on IoC2 monitoring for analgesic depth
[6]. We hypothesized that IoC2 monitoring would helpistributed under the terms of the Creative Commons Attribution 4.0
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plied IoC1 and IoC2 to the use of a sedative agent,
propofol, and most importantly, an analgesic agent,
remifentanil. Furthermore, we evaluated the effective-
ness of IoC monitoring for anesthetic depth (IoC1
and IoC2) versus commonly used vital sign monitor-
ing based on factors such as blood pressure and heart
rate.
Methods
Study design and patients
This study was a randomized single-blind prospective
trial. It was registered with http://www.chictr.org.cn/
index.aspx (ChiCTR-TRC-13004101). This study was
approved by the Medical Ethics Committee of Liao-
cheng People’s Hospital (approval number 2013XJS-
023). In total, 120 patients who were undergoing
elective unilateral modified radical mastectomy under
total intravenous anesthesia (TIVA) from 20 January
2014 to 1 June 2014 were consecutively enrolled at
the Liaocheng People’s Hospital. Inclusion criteriaFig. 1 Consort patients flow diagramwere: (1) American Society of Anesthesiologists (ASA)
class I or II; (2) age 18–65 years old; and (3) body
mass index (BMI) 18–30 kg/m2. Exclusion criteria
were: (1) pregnancy; (2) allergy to the agents used in
the study; (3) hypertension; (4) hypotension; (5)
tachycardia; or (6) bradycardia. Signed informed con-
sent was obtained from all participants. They were
randomized 1:1 to the trial group (T group, n = 60) or
the control group (C group, n = 60).
Randomization method: 120 opaque and sealed enve-
lopes marked from 1 to 120 were prepared by the re-
searchers, each containing one card written with a
random number generated using SPSS 17.0 (IBM,
Armonk, NY, USA). If the random number was odd, the
patient was allocated to the T group; otherwise the pa-
tient was allocated to the C group. Randomization was
implemented by a designated individual who did not
participate in the subsequent inclusion of patients. The
single-blind method was applied to the patients. The T
group was monitored using IoC for depth of anesthesia
monitoring while the C group was not (Fig. 1).
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surgical method was changed peri-operatively or if the
anesthetics were finally not used according to the study
protocol, for any reason. Other conditions affecting this
trial (e.g., airway obstruction, secondary anesthesia given
before the patient completely regained consciousness)
also led to patient exclusion.
Anesthesia
After admission to the operating room, the patient was
administered 8 ml/kg of Ringer’s solution with an intra-
operative maintenance dose of 4 ml kg-1 h-1. Baseline
blood pressure and heart rate were acquired 15 min after
admission to the operating room. Both the T and C
groups were induced using the Marsh pharmacokinetic
model-based target-controlled infusion of propofol.
Based on an initial plasma target concentration of
4.0 μg/ml, fentanyl was intravenously injected at 3 μg/kg
and cisatracurium at 0.2 mg/kg. Tracheal intubation was
performed for mechanical ventilation when satisfactory
muscle relaxation was achieved (about 3 min) according
to train-of-four (TOF) stimulation evaluation, followed
by connection to an anesthetic machine (Drägerwerk
AG & Co. KGaA, Lübeck, Germany) for volume-
controlled ventilation with a tidal volume of 8 ml/kg, a
respiratory rate of 12/min, a respiratory ratio of 1:2, and
a pressure of end-tidal carbon dioxide (PETCO2) of 35–
45 mmHg. At 45 min of surgery, 0.2 mg/kg of cisatra-
curium was administered for muscle relaxation.
Anesthesia monitoring
For both groups, non-invasive blood pressure, electro-
cardiogram (ECG), peripheral oxygen saturation, and
PETCO2 were routinely monitored. The T group received
IoC1 monitoring for depth of sedation and IoC2 moni-
toring for depth of analgesia (Angel-6000D Multi-
parameter Anesthesia Monitor, Shenzhen Weihaokang
Medical Technology Co., Ltd, Guangdong, China).
For the generation of IoC [2, 7], the recorded elec-
troencephalogram (EEG) signals are divided into lin-
ear and non-linear modules and partitioned using a
symbolic dynamics approach. Each part is then la-
beled by a symbol to convert time series to symbol
sequences. Finally, IoC1 is acquired using an adaptive
neuro fuzzy inference system based on β ratio and
burst suppression rate [8] and IoC2 is derived. The
index of depth of sedation, IoC1, ranges from 0 to
99 and is controlled to be within 40–60 during the
operative period, with IoC1 > 60 indicating insuffi-
cient use of sedative agents while IoC1 < 40 indicates
excessive sedation. The index of depth of analgesic,
IoC2, ranges from 0 to 99 and is controlled to be
within 30–50 during the operative period, with
IoC2 > 50 indicating insufficient use of analgesicagents and IoC2 < 30 indicating excessive analgesic ef-
fects. Target-controlled infusion is a common, convenient,
and accurate administration approach for intravenous
anesthesia. In this study, target-controlled infusion was
used to record the infusion duration and total dosage of
propofol and remifentanil accurately. Previous studies
have shown good consistency between IoC and bispectral
index [9–14].
During anesthesia, anesthetists adjusted the dosages
of propofol and remifentanil according to the changes
in IoC1 and IoC2. IoC1, a sedative index, was used as
the guide for the adjustment of propofol target con-
centration, which was increased by 0.5 μg/ml per ad-
justment when IoC1 > 60 and was increased by 1 μg/
ml when body movements were observed. Target con-
centration was decreased by 0.5 μg/ml per adjustment
when IoC1 < 40, with a maintenance value between 40
and 60. IoC2, an analgesic index, was used as the
guide for the adjustment of remifentanil target con-
centration (based on the Minto remifentanil pharma-
cokinetic parameter set), in which the target
concentration was increased by 1 ng/ml per adjust-
ment when IoC2 > 50 but was decreased by 1 ng/ml
per adjustment when IoC2 < 30, with the maintenance
value between 30 and 50. The C Group was not moni-
tored using IoC, and the doses of propofol and remi-
fentanil were adjusted by the anesthetists according to
vital signs such as blood pressure and heart rate so as
to control the fluctuation of blood pressure and heart
rate within 20 % of baseline values. Meantime, adverse
events, such as hypertension, hypotension, tachycar-
dia, and bradycardia, were recorded. The patient’s
quality of anesthetic recovery was recorded at the
completion of anesthesia.
Data collection
The following indexes were recorded: (1) general pa-
tient data (age, sex, weight, height, BMI, baseline blood
pressure, and heart rate); (2) remifentanil (adjustment
frequency of target concentration, infusion duration,
and mean dosage); (3) propofol (adjustment frequency
of target concentration, infusion duration, and mean
dosage); (4) frequencies of intraoperative adverse events
(hypertension, hypotension, tachycardia, bradycardia,
and body movements); and (5) quality of anesthetic re-
covery [voluntary eye opening, extubation time, awak-
ening score (OAA/S score), and whether the patient
showed intraoperative awareness].
Hypertension was defined as intraoperative systolic pres-
sure >160 mmHg, hypotension as intraoperative systolic
pressure <90 mmHg, tachycardia as heart rate >90 bpm,
and bradycardia as heart rate <45 bpm. Voluntary eye
opening time was defined as the interval from stop-
ping the infusion of narcotic drugs to showing
Table 1 Comparison of general data between the two groups
(mean ± SD)
T group (n = 54) C group (n = 53) P
Age (years) 47 ± 7 48 ± 8 0.745
Weight (kg) 63 ± 9 63 ± 8 0.983
Height (cm) 160 ± 5 159 ± 4 0.464
BMI (kg/m2) 25 ± 3 25 ± 3 0.804
Systolic pressure (mmHg) 130 ± 8 128 ± 10 0.517
Diastolic pressure (mmHg) 77 ± 6 74 ± 7 0.135
Heart rate (bpm) 76 ± 7 75 ± 7 0.291
BMI body mass index
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name in a normal voice. The OAA/S score was
assessed at the moment of extubation. Intraoperative
awareness (using modified Brice questionnaires) was
assessed after the patient sobered up.
Outcomes
The primary outcome was the dose of remifentanil. The
secondary outcomes were remifentanil adjustment fre-
quency, infusion duration, intraoperative adverse events,
and quality of anesthetic recovery.
Statistical analysis
The sample size was calculated using a significance
level α = 0.05 and test power 1 – β = 0.80. Based on a
preliminary trial performed with 20 patients (unpub-
lished data), the mean dosage of remifentanil was 3.0 ±
1.1 μg kg-1 h-1 in the T group and a significant differ-
ence in dosage was defined as a fluctuation ≥20 %
compared with the C group. Based on the formula pro-
vided by Chow et al. [15] for the calculation of clinical
trial sample size, 46 patients were required in each
group. However, a total of 120 patients were enrolled
in consideration of a dropout rate of 25 %.
All data were analyzed using SPSS 17.0 (IBM, Armonk,
NY, USA). Continuous data are shown as mean ± stand-
ard deviation (SD). Between-group comparisons were
performed using the independent sample t test or the
rank sum test. Categorical data were compared using
the chi-square test. A P value <0.05 was considered sta-
tistically significant.
Results
A total of 120 patients with breast cancer were enrolled
in January to June 2014 and randomly assigned to the T
group (n = 60) or C group (n = 60). Thirteen patients
were excluded. Six patients were excluded from the T
group due to a change of the surgical method (n = 3),
airway obstruction at extubation (n = 1), or venous path-
way obstruction (n = 2). Seven patients were excluded
from the C group for non-compliance to trial protocol
(n = 3), change of the surgical method (n = 3), or second-
ary anesthesia due to a small vascular rupture before
extubation (n = 1). Therefore, 54 and 53 patients were
included in the final analyses for the T and C groups, re-
spectively (Fig. 1).
The two groups were not significantly different in age,
height, weight, BMI, systolic pressure, diastolic pressure,
and heart rate (all P > 0.05) (Table 1).
As shown in Table 2, remifentanil infusion duration
was not significantly different between the two groups
(P > 0.05), but the adjustment frequency of remifenta-
nil target concentration and mean dosage were differ-
ent (P < 0.05). Comparing the use of propofol andquality of anesthetic recovery, the groups were not sig-
nificantly different either in adjustment frequency or
in mean dosage, with similar voluntary eye opening,
extubation time, and awakening score (all P > 0.05).
As shown in Table 3 (intraoperative adverse events),
although some apparent differences in frequencies of
hypertension (9 % versus 17 %, P = 0.24), hypotension
(11 % versus 21 %, P = 0.17), tachycardia (0 % versus
4 %, P = 0.15), bradycardia (17 % versus 8 %, P = 0.15),
body movement (11 % versus 19 %, P = 0.26), and num-
ber of patients with adverse events (35 % versus 47 %,
P = 0.21) could be observed, they were not statistically
significant (all P > 0.05). Nevertheless, the T group
showed significantly less total adverse events (48 %
versus 68 %, P < 0.05).Discussion
This study investigated the effects of IoC1 and IoC2
monitoring on remifentanil dosage. Results showed
that compared with the C group, the mean remifen-
tanil dose was significantly higher in the T group
during the anesthetic period, as were the adjustment
frequency of target-controlled infusion, but there was
no difference in infusion duration. Voluntary eye
opening, extubation time, and recovery score were
not significantly different between the two groups.
Total adverse events were significantly reduced in
the T group.
Some studies have shown that pain can induce
changes in EEG power [16–18]. Jensen et al. [2] con-
firmed that IoC1 (qCON) can reliably predict the
disappearance of eyelash reflex (or, the disappearance
of awareness) during TIVA using propofol and remi-
fentanil. Moreover, with similar concentrations of an-
esthetics, IoC2 (qNOX) can predict the occurrence of
body movements to nociceptive stimuli. In the
present study, nociceptive stimuli mainly occurred
during anesthesia or surgical procedures such as
Table 2 Comparison of use of remifentanil and propofol and quality of anesthetic recovery between the two groups (mean ± SD)
Item T group (n = 54) C group (n = 53) P
Use of remifentanil
Adjustment frequency of target concentration (times/surgery) 2.9 ± 1.9a 2.0 ± 0.2a 0.009a
Infusion duration (h) 1.1 ± 0.6 1.3 ± 0.7 0.428
Mean dose (μg kg-1 h-1) 3.8 ± 1.9 3.2 ± 1.2 0.003
Use of propofol
Adjustment frequency of target concentration (times/surgery) 3.0 ± 2.0a 3.0 ± 1.9a 0.444a
Infusion duration (h) 1.6 ± 0.5 1.9 ± 0.6 0.523
Mean dosage (μg kg-1 h-1) 8.8 ± 1.1 8.3 ± 1.0 0.903
Quality of anesthetic recovery
Voluntary eye opening (min) 5.4 ± 3.1 6.2 ± 2.3 0.782
Extubation time (min) 9.8 ± 6.1 9.3 ± 5.7 0.816
Awakening score 3.9 ± 0.7 4.0 ± 0.9 0.960
a Indicates the results of rank sum test
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tion of mammary tissues, and axillary lymph node
dissection. This study revealed a slight delay (around
1.5–2 min) in IoC2 reduction compared with IoC1
during anesthesia induction, possibly due to a slower
action (1 min) of remifentanil versus propofol (30–
40 s) or due to the computational errors in the cal-
culation of IoC2 based on IoC1, or both.
Like EEG curves, IoC1 and IoC2 curves constantly
change during the maintenance of anesthesia, and they
are not smooth. This demonstrates that the so-called
depth of anesthesia is essentially a state of the central ner-
vous system that is affected by the interactions between
the irritations from nociceptive stimuli and the inhibitory
effects of anesthetic agents. In other words, it is a func-
tional state of the central nervous system occurring when
surgical stimulation dynamically balances against the con-
trol effects of general anesthetics, indicating that IoC1 and
IoC2 will still slightly fluctuate due to surgical stimuli al-
though the effect compartment concentrations of propofol
and remifentanil or depth of anesthesia is relatively stable.
Based on the characteristics of IoC1 and IoC2 and based
on our clinical experience, the doses of propofol andTable 3 Intraoperative adverse events in the two groups
Item T group (n =
Hypertension 5 (9 %)
Hypotension 6 (11 %)
Tachycardia 0
Bradycardia 9 (17 %)
Body movements 6 (11 %)
Number of patients with adverse events 19 (35 %)
Intraoperative awareness 0
Total adverse events 26 (48 %)remifentanil should be changed when both IoC1 and IoC2
exceed or are lower than their reference ranges for over
2 min, or when both indexes exceed more than 20 within
1 min, to avoid frequent adjustments of infusion speed.
Nevertheless, trials should look specifically at the most
optimal protocols for changes in anesthetic doses using
IoC1 and IoC2.
In the C group, the doses of propofol and remifenta-
nil were adjusted based on the patient’s baseline blood
pressure and heart rate to make them fluctuate within
80–120 % of baseline values during surgery. Although
the adjustment frequency and mean dose of remifenta-
nil were higher in the T group than in the C group, the
T group showed more stable hemodynamics, and smaller
frequencies of hypertension, hypotension, and adverse
events. In the T group, a relatively high incidence of
bradycardia may have resulted from the side effects of
slowing down the heart rate by remifentanil, but as an
ultra-short-acting opioid analgesic, remifentanil does not
affect the patient’s awakening. During maintenance of
anesthesia, the effect compartment concentration of pro-
pofol was kept within 2.5–6.0 μg/ml in both groups, but
remifentanil showed a huge variation among patients,54) C group (n = 53) P
9 (17 %) 0.236
11 (21 %) 0.173
2 (4 %) 0.150
4 (8 %) 0.149
10 (19 %) 0.261
25 (47 %) 0.208
0 1.000
36 (68 %) 0.038
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0–7 ng/ml.
In TIVA, the sedative agent (propofol) and analgesics
(fentanyl and remifentanil) do not show muscle relaxation
effects, and there is a need for administration of muscle
relaxants. During surgery, the muscle relaxant cisatracur-
ium was administered at 45 min with 0.2 mg/kg. In the T
group, seven patients showed body movements before
muscle relaxants were administered, although their
hemodynamic indexes reached the lower limits, and inter-
estingly, three patients showed body movements even
with a low yet normal index of depth of anesthesia, indi-
cating that the reliability of IoC monitoring for depth of
anesthesia in predicting body movements should be fur-
ther studied in the future.
In the present study, five patients who underwent pre-
operative chemotherapy showed higher IoC1 and IoC2
than the reference ranges for about 75 % of the time
(among whom some showed light anesthesia with IoC1
and IoC2 reaching 73–88, which almost indicated
regained consciousness), although their effect compart-
ment concentrations of propofol and remifentanil were
3.5–5.5 μg/ml and 2–5 ng/ml, respectively, and their
hemodynamic indexes were within the reference ranges.
According to previous studies, preoperative chemotherapy
can damage liver and renal functions and the nervous sys-
tem [19, 20], and chemotherapy drugs can boost the ef-
fects of and reduce the use of anesthetic drugs. However,
in this study, the doses of anesthetics were higher in the
patients with breast cancer who underwent preoperative
chemotherapy. They also showed faster metabolism of
muscle relaxants and faster recovery of spontaneous res-
piration, inconsistent with previous studies. Since only a
few patients (17 in the C group and 12 in the T group)
with preoperative chemotherapy were included in this
study, the above inconsistency is not explainable and thus,
should be further validated by other studies. Unlike bis-
pectral index monitoring, the monitor used in this study
does not require special electrodes, which reduces medical
expenditures and promotes clinical propagation and appli-
cation. Normally, the EEG amplitude is within 0–200 μV,
about 1/400 of cardiac electrical activities; hence, com-
pared with ECG, it is more easily affected by widely used
high-frequency electrical equipment such as an electro-
coagulation electrotome. We chose patients undergoing
mastectomy because the electrotome used for surgery is
low in power and distant from the site of data collection
and as a result, the effects of interference are smaller.
Nonetheless, this disadvantage may still affect its further
clinical application and some improvements should be
made on surgical site selection, materials for production
of the monitor, and filtering clutter, among others.
This study suffers from some limitations. The sample
size was small. We only studied the application of IoCmonitoring to TIVA and thus its effectiveness with in-
haled anesthesia is unclear. In addition, only female pa-
tients were included in our study, but the possible
differences of pharmacokinetics with male patients
should be considered. Fentanyl was used for intubation,
but the same dose was used in both groups; therefore, it
should not influence the comparison between the two
groups. Importantly, propofol administration was not
standardized and was based on IoC1, therefore introdu-
cing variability that could mask the real effects of IoC2
monitoring. In addition, standard monitoring parame-
ters, such as bispectral index, should be included in fu-
ture studies to correlate the parameters with IoC2.
Finally, some confounding factors that may affect our re-
sults have not been controlled and additional studies are
necessary to examine the impact of neoadjuvant chemo-
therapy on IoC2.
Conclusions
In summary, EEG anesthesia depth index (IoC) monitor-
ing during TIVA is safe and effective for patients with
breast cancer. IoC1-targeted propofol dosing does not
seem to be significantly different to hemodynamic-based
monitoring, whereas the application of IoC2 might be
used to guide the use of remifentanil. It might reduce
the occurrence of adverse events and keep
hemodynamics more stable, but its reliability in predict-
ing body movements as well as the anti-interference
ability should be further improved.
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